GSK3A and Obesity: Previously, in the developing obesity model, we saw a reduction in cardiac GSK-3α activity (decreased GSK-3α phosphorylation) in HF-fed CM-GSK-3β KO hearts leading to an impairment in GSK-3-β-catenin degradation pathway and cardiac dysfunction [6].